Goal
Sexual function
Central desire pathways, not erectile mechanics. Four compounds, and the ceilings matter.
Sexual function here means desire and arousal rather than erectile mechanics; PDE5 inhibitors are a different category and are not in this dataset. Everything on this page acts centrally — on melanocortin, kisspeptin and oxytocin pathways — which is why the effect is on wanting rather than on plumbing, and why the side effects read as nausea and flushing rather than anything local.
PT-141 (bremelanotide) at 5 is the only compound in the entire library approved for the goal it is listed under: FDA-approved in 2019 as Vyleesi for acquired, generalised hypoactive sexual desire disorder in premenopausal women, dosed at 1.75 mg as needed, no more than once in twenty-four hours and no more than eight times a month. Efficacy in men is not established. Kisspeptin-10 at 4 sits upstream of the entire hypothalamic-pituitary-gonadal axis, with unusually well-controlled acute human data and nothing at all published on repeated self-administration. Oxytocin at 4 is an approved obstetric drug whose use here rests on an intranasal social-cognition literature that is acute, single-dose and contested — and it is a hard contraindication in pregnancy, because its approved pharmacological action is to make the uterus contract. Melanotan II at 3 shares PT-141’s receptor family, which is why erections and nausea are common to both.
Ceilings matter more here than on any other page. PT-141 has a label maximum and nothing above it is supported by anything. Kisspeptin desensitises with continuous or frequent exposure — more is not better, it is less. Blood pressure is the recurring safety theme across the melanocortins. And if desire has dropped noticeably rather than always been low, testosterone, thyroid, sleep, depression and current medications are the things to rule out before reaching for anything on this list.
How to read this
Match — how squarely it aims here
The weight the dataset gives this compound for this goal, 1 to 5. It describes intent and mechanism, not benefit, and not direction: a 5 means the compound acts hard on the system in question.
5/5Match strength 5 of 5primary useEvidence — whether anyone has shown it
Read from the compound’s evidence note and handling grade, for the compound as a whole rather than for this goal alone. A 5/5 match on animal data is a hypothesis, not a result.
- Human trialsRandomized or controlled human trials exist, or the compound holds a regulatory approval somewhere. Trials existing is not the same as trials succeeding — some of these were negative.
- Some human dataPublished human work exists but is small, early-phase, acute, or from a single group that nobody has replicated.
- Animal data onlyThe case rests on rodent and cell work. Doses shown are extrapolated, not established in people.
- Anecdotal onlyNo published trial record of any kind. Every number comes from vendor packaging and community practice.
4 compounds, strongest match first
Ranked for sexual function
Match 5/5 · Primary use
1
Match 4/5 · Strong secondary
2
Match 3/5 · Meaningful contributor
1
Named stacks
Protocols built around this goal
No named protocol in the library targets sexual function directly. That is usually a sign the goal is run as a single compound rather than a stack — browse every protocol to see what the library does cover.
Not sure this is your goal
Most people arrive wanting two or three of these at once, and the honest answer is usually to pick one and run it properly. The quiz weighs your goals against your experience, the routes you will tolerate and your contraindications, then shows its reasoning rather than just a name.
Take the quizOther goals
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.